Trial Profile

A Phase 2 Study to Assess the Safety, Efficacy of FLX475 Combined with Pembrolizumab in Patients with Advanced or Metastatic Gastric Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; Tivumecirnon (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Sponsors Hanmi Pharmaceutical

Most Recent Events

17 Feb 2025 Results published in the Hanmi Pharmaceutical Media Release.
17 Feb 2025 According to a Hanmi Pharmaceutical media release, results from this study presented at American Society of Clinical Oncology GI Cancers Symposium held in San Francisco, USA, from January 23 to 25.
01 Dec 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com